FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Clinical trial NCT06788990 · RECRUITING

Trial details

NCT number: NCT06788990
Sponsor: Bicara Therapeutics
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma

Start date: 2025-01-28
Primary completion: 2028-04-01
Enrollment: 650

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.